We invite the submission of proposals for clinical poster presentations at the 5th Innsbruck/Konstanz Targeted Temperature Management Symposium. Poster presentations will be an integral part of the conference, with a session for interactive discussion between presenters and attendees. In order to maintain interactive and exciting poster presentations, at least one presenter per accepted poster is required to attend the conference.

Poster presentations must be in English. The submission must include a 2-page abstract, plus a draft of the final poster. Please be aware that the poster draft is mandatory.

All submitted materials must be in PDF format with embedded fonts. Two-page abstracts will be included in the Conference Abstracts. Poster abstracts and posters will be submitted through the 5th Innsbruck/Konstanz Targeted Temperature Management Symposium website.

For questions or further information, please contact: register@chilling-at-the-beach.eu
Symposium 1: Means of Temperature management - do techniques matter
08:15 - 08:35 Endovascular cooling from cold saline to sophisticated central venous lines
08:35 - 08:55 Physical strategies - cool the skin or the mucosa - surface cooling pads, transnasal, transcutal, gastric lavage
08:55 - 09:15 Achieving controlled TIM by pharmacological means - will we be cooling by drugs only in the future?
10:15 - 10:35 The optimal TIM dosage - Duration - TIM 48 trial
10:35 - 10:55 The optimal TIM dosage - Target Temperature - The FROST trial
11:55 - 11:35 The optimal temperature management in cardiovascular diseases beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?

Symposium 2: When the heart fails to work, brain and Co suffer: TIM after Cardiac Arrest
09:55 - 10:15 History of TIM in Cardio Arrest - what can we learn from the past
10:15 - 10:35 TIM in Cardio Arrest - where are we 2017 and what are the next goals
10:35 - 10:55 The optimal TIM dosage - Duration - The TIM 48 trial
10:55 - 11:15 The optimal TIM dosage - Target Temperature - The FROST trial
11:15 - 11:35 Targeted temperature management in cardiovascular disease beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?

Symposium 3: TIM in neurological injury
13:00 - 13:20 TIM and ICP: Still a case for TIM
13:20 - 13:40 Prophylactic controlled normothermia is the future in the neurological care patient
13:40 - 14:20 Beyond ICP and CPP: brain metabolism under fever and TIM
14:20 - 14:40 Can TIM avoid secondary neuronal injury - insights from the pathophysiology of TIM
14:40 - 14:40 Where do we head to - neuroprotection a mystery?

Symposium 4: TIM in neonatology - The finer the more careful attention is needed
15:00 - 15:20 Neonatal encephalopathy - Update on therapeutic hypothermia and other novel therapies
15:20 - 15:40 Are small brains different from adults - why is therapeutic hypothermia so effective in newborns?
15:40 - 16:00 Neonatal hypoxic encephalopathy treated with therapeutic hypothermia: mild to longterm prognosis
16:00 -16:20 MRI and spectroscopy in (near) term neonates with perinatal asphyxia and therapeutic hypothermia
16:20 -16:40 Morbidity and mortality is associated with rewarming in very low birth weight infants

Symposium 5: Perioperative Temperature Management
08:08 - 08:20 Guidelines for prevention of perioperative hypothermia
08:20 - 08:40 Temperature Management in Burn Patients
08:40 - 09:00 TIM in the operating theatre - the forgotten therapeutic approach
09:00 - 09:20 TIM in the perioperative setting - influence on outcome

Symposium 6: Attacked from the heart - keep cool
09:35 - 09:55 Cooling in STEMI - early success and limitations
09:55 - 10:15 Infarct size reduction by preperfusion moderate therapeutic hypothermia
10:15 - 10:35 STEMI cooling - feasible and safe
10:35 - 10:55 COOL AN EU - a pilot trial

Symposium 7: TIM in ICU and thereafter - Part I
11:10 - 11:30 TIM in the ICU: a necessity with pitfalls?
11:30 - 11:50 The role of inflammation in targeted temperature management - friend or foe
11:50 - 12:10 Post cardiac arrest / Post ICU syndrome and long-term neurological recovery in patients treated with TIM
12:10 - 12:30 The saga of temperature variability
12:30 - 12:50 Acute liver failure: pathophysiological concepts for brain injury and treatment options using TIM

Symposium 8: TIM in ICU and thereafter - Part II
13:50 - 14:10 Prophylactic antibiotics in ICU patients treated with TIM
14:10 - 14:30 Effect of TIM on brain imaging using MRI
14:30 - 14:50 Cardiopulmonary responses during the cooling and the extracorporeal life support rewarming phases
14:50 - 15:10 Intracranial pressure during the rewarming period after mild therapeutic hypothermia
15:10 - 15:30 Early goal-directed management for the prevention of incidental hypothermia related morbidity and mortality in severely injured trauma patients

Symposium 9: ICU- and Stroke Unit nurses - absolutely essential and indispensable in TIM
15:45 - 16:05 Temperature in the emergency room: optimal management - in the area of accident and emergency practice
16:05 - 16:25 ICU and Stroke Unit nurses: essential to detect/avoid fever and maintain TIM
16:25 - 16:45 Patients treated with therapeutic hypothermia: the ICU/Stroke Unit nurse: essential to anticipate trouble
16:45 - 17:05 The impact of the ICU and Stroke Unit nurse on outcome

Symposium 10: The role of inflammation in targeted temperature management - friend or foe
16:45 - 16:50 Achieving controlled TIM by pharmacological means - will we be cooling by drugs only in the future?

Symposium 11: When the heart fails to work, brain and Co suffer: TIM after Cardiac Arrest
09:55 - 10:15 History of TIM in Cardio Arrest - what can we learn from the past
10:15 - 10:35 TIM in Cardio Arrest - where are we 2017 and what are the next goals
10:35 - 10:55 The optimal TIM dosage - Duration - The TIM 48 trial
10:55 - 11:15 The optimal TIM dosage - Target Temperature - The FROST trial
11:15 - 11:35 Targeted temperature management in cardiovascular disease beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?

Symposium 12: When the heart fails to work, brain and Co suffer: TIM after Cardiac Arrest
09:55 - 11:15 History of TIM in Cardio Arrest - what can we learn from the past
10:15 - 11:35 TIM in Cardio Arrest - where are we 2017 and what are the next goals
10:35 - 10:55 The optimal TIM dosage - Duration - The TIM 48 trial
10:55 - 11:15 The optimal TIM dosage - Target Temperature - The FROST trial
11:15 - 11:35 Targeted temperature management in cardiovascular disease beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?

Symposium 13: When the heart fails to work, brain and Co suffer: TIM after Cardiac Arrest
10:15 - 10:35 TIM in Cardio Arrest - where are we 2017 and what are the next goals
10:35 - 10:55 The optimal TIM dosage - Duration - The TIM 48 trial
10:55 - 11:15 The optimal TIM dosage - Target Temperature - The FROST trial
11:15 - 11:35 Targeted temperature management in cardiovascular disease beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?

Symposium 14: When the heart fails to work, brain and Co suffer: TIM after Cardiac Arrest
11:15 - 11:35 History of TIM in Cardio Arrest - what can we learn from the past
10:15 - 11:35 TIM in Cardio Arrest - where are we 2017 and what are the next goals
10:35 - 10:55 The optimal TIM dosage - Duration - The TIM 48 trial
10:55 - 11:15 The optimal TIM dosage - Target Temperature - The FROST trial
11:15 - 11:35 Targeted temperature management in cardiovascular disease beyond cardiac arrest
11:35 - 11:55 Effects of Hypothermia and TIM on drug disposition and response following cardiac arrest - do we need to titrate or monitor drugs differently under TIM?